Chimeric Therapeutics Delays Financials Amidst Capital Drive
Company Announcements

Chimeric Therapeutics Delays Financials Amidst Capital Drive

Chimeric Therapeutics Ltd. (AU:CHM) has released an update.

Chimeric Therapeutics has announced a delay in lodging its full year financial statements, owing to a pending capital raising announcement anticipated to complete by 18 October 2024. The Australian clinical-stage cell therapy company is known for its innovative cancer treatments and has a diverse portfolio, including therapies currently in clinical trials. Chimeric is committed to the discovery, development, and commercialization of groundbreaking cell therapies aimed at curing cancer.

For further insights into AU:CHM stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App